Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
3 hedge funds and large institutions have $8.61M invested in Hepion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
44% less capital invested
Capital invested by funds: $15.3M → $8.61M (-$6.72M)
50% less funds holding
Funds holding: 6 → 3 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$834K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$4.41M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$3.4M |
| 3 |
TA
Teachers Advisors
New York
|
-$1.82M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$72K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
26
Thompson Davis & Co
Richmond,
Virginia
| $5K | – | – | – |
|
27
Creative Planning
Overland Park,
Kansas
| $3K | – | – | – |
|
|
DADC
28
D.A. Davidson & Co
Great Falls,
Montana
| $3K | – | – | – |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | – | – | – |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
VIA
31
Vantage Investment Advisors
State College,
Pennsylvania
| $2K | – | – | – |
|
|
AG
32
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
33
SEI Investments
Oaks,
Pennsylvania
| $1K | – | – | – |
|
|
EI
34
EAM Investors
Solana Beach,
California
| – | -$3.4M | -1 | Closed |
|
|
TA
35
Teachers Advisors
New York
| – | -$1.82M | -1 | Closed |
|
|
TCIM
36
TIAA CREF Investment Management
New York
| – | -$4.41M | -1 | Closed |
|
|
NFG
37
Next Financial Group
Houston,
Texas
| – | -$2K | – | – |
|
|
38
Russell Investments Group
London,
United Kingdom
| – | -$72K | – | – |
|
|
SBL
39
Sargent Bickham Lagudis
Boulder,
Colorado
| – | -$1K | – | – |
|
|
TSS
40
Two Sigma Securities
New York
| – | -$18K | – | – |
|
HEPA Hedge Fund Activity: Q1 2017 in Review
3 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2017, worth a combined $8.61M — down 44% from $15.3M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of HEPA and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $834K. The largest seller was TIAA CREF Investment Management, exiting entirely with an estimated $4.41M sold.
- 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2017, down from 6 in Q4 2016.
- Funds reported $8.61M of Hepion Pharmaceuticals stock for Q1 2017, down 44% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of -3 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2017 was Vanguard Group, an estimated $834K added.
- The largest Hepion Pharmaceuticals seller in Q1 2017 was TIAA CREF Investment Management, an estimated $4.41M sold.
Based on aggregated 13F filings for Q1 2017.